FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387025105> ?p ?o ?g. }

• W4387025105 abstract "New oral anticoagulants (NOACs) have been becoming prevalent in recent years and are increasingly used in the treatment of port vein thrombosis. The difference of the efficacy and safety between rivaroxaban and dabigatran remains unclear in the treatment of cirrhotic patients with acute portal vein thrombosis (PVT).This retrospective study included all consecutive cirrhotic patients with acute portal vein thrombosis in our institute from January 2020 to December 2021. The patients received oral anticoagulation with rivaroxaban or dabigatran. The demographic, clinical, and imaging data of patients were collected. The diagnosis of acute PVT was confirmed by imaging examinations. The severity of liver cirrhosis was assessed using Child-Pugh score and Model for End-Stage Liver Disease (MELD) score. Outcomes included recanalization (complete, partial, and persistent occlusion), liver function, bleedings, and survival. The log-rank test was used to compare Kaplan-Meier distributions of time-to-event outcomes. The Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs).A total of 94 patients were included, 52 patients (55%) received rivaroxaban and 42 (45%) with dabigatran. The complete and partial recanalization of PVT was observed in 41 patients. There was no significant difference in complete recanalization, partial recanalization, and persistent occlusion between the two groups. With multivariate analysis, D-dimer (HR 1.165, 95% CI 1.036-1.311, p = 0.011) was independent predictors of complete recanalization. The Child-Pugh score (p = 0.001) was significantly improved in both two groups after anticoagulation, respectively. However, there was no difference between the two groups. The probability of survival was 94%, 95% in the rivaroxaban and dabigatran groups (log-rank p = 0.830). Major bleedings were reported in 3 patients (6%) in rivaroxaban group and 1 patient (2%) in dabigatran group (p = 0.646). Six patients (12%) in rivaroxaban group experienced minor bleeding, and five (12%) from dabigatran group (p = 0.691).The efficacy and safety were comparable between rivaroxaban and dabigatran in the treatment of cirrhotic patients with acute portal vein thrombosis. And D-dimer can contribute to the prediction of PVT recanalization in cirrhotic patients." @default.
• W4387025105 created "2023-09-26" @default.
• W4387025105 creator A5015756887 @default.
• W4387025105 creator A5017133635 @default.
• W4387025105 creator A5039810634 @default.
• W4387025105 creator A5043655160 @default.
• W4387025105 creator A5079519883 @default.
• W4387025105 creator A5086703398 @default.
• W4387025105 creator A5086790957 @default.
• W4387025105 date "2023-09-25" @default.
• W4387025105 modified "2023-10-08" @default.
• W4387025105 title "Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis" @default.
• W4387025105 cites W1559210752 @default.
• W4387025105 cites W1619867218 @default.
• W4387025105 cites W1987880263 @default.
• W4387025105 cites W1993340951 @default.
• W4387025105 cites W1993638317 @default.
• W4387025105 cites W2009411164 @default.
• W4387025105 cites W2011620007 @default.
• W4387025105 cites W2032537572 @default.
• W4387025105 cites W2069878206 @default.
• W4387025105 cites W2113561246 @default.
• W4387025105 cites W2124347738 @default.
• W4387025105 cites W2152623033 @default.
• W4387025105 cites W2169804384 @default.
• W4387025105 cites W2189770508 @default.
• W4387025105 cites W2191613287 @default.
• W4387025105 cites W2549557285 @default.
• W4387025105 cites W2588625607 @default.
• W4387025105 cites W2596888165 @default.
• W4387025105 cites W2610258648 @default.
• W4387025105 cites W2808876361 @default.
• W4387025105 cites W2903882391 @default.
• W4387025105 cites W2909073103 @default.
• W4387025105 cites W2944710660 @default.
• W4387025105 cites W2950337259 @default.
• W4387025105 cites W2974223976 @default.
• W4387025105 cites W2991907358 @default.
• W4387025105 cites W2995175034 @default.
• W4387025105 cites W3009006336 @default.
• W4387025105 cites W3017753812 @default.
• W4387025105 cites W3034331236 @default.
• W4387025105 cites W3082394541 @default.
• W4387025105 cites W3101262616 @default.
• W4387025105 cites W3103618496 @default.
• W4387025105 cites W3110213440 @default.
• W4387025105 cites W3128709119 @default.
• W4387025105 cites W3155896785 @default.
• W4387025105 cites W3157371466 @default.
• W4387025105 cites W3158507545 @default.
• W4387025105 cites W3164084884 @default.
• W4387025105 cites W3183297595 @default.
• W4387025105 cites W3185684932 @default.
• W4387025105 cites W3203499492 @default.
• W4387025105 cites W4200473175 @default.
• W4387025105 cites W4214706159 @default.
• W4387025105 cites W4220829984 @default.
• W4387025105 cites W4221055333 @default.
• W4387025105 cites W4225277568 @default.
• W4387025105 cites W4294991531 @default.
• W4387025105 cites W4317871334 @default.
• W4387025105 doi "https://doi.org/10.1186/s12876-023-02960-8" @default.
• W4387025105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37749527" @default.
• W4387025105 hasPublicationYear "2023" @default.
• W4387025105 type Work @default.
• W4387025105 citedByCount "0" @default.
• W4387025105 crossrefType "journal-article" @default.
• W4387025105 hasAuthorship W4387025105A5015756887 @default.
• W4387025105 hasAuthorship W4387025105A5017133635 @default.
• W4387025105 hasAuthorship W4387025105A5039810634 @default.
• W4387025105 hasAuthorship W4387025105A5043655160 @default.
• W4387025105 hasAuthorship W4387025105A5079519883 @default.
• W4387025105 hasAuthorship W4387025105A5086703398 @default.
• W4387025105 hasAuthorship W4387025105A5086790957 @default.
• W4387025105 hasBestOaLocation W43870251051 @default.
• W4387025105 hasConcept C126322002 @default.
• W4387025105 hasConcept C141071460 @default.
• W4387025105 hasConcept C207103383 @default.
• W4387025105 hasConcept C2776301958 @default.
• W4387025105 hasConcept C2778661090 @default.
• W4387025105 hasConcept C2778800853 @default.
• W4387025105 hasConcept C2778810321 @default.
• W4387025105 hasConcept C2779161974 @default.
• W4387025105 hasConcept C2780868729 @default.
• W4387025105 hasConcept C44249647 @default.
• W4387025105 hasConcept C50382708 @default.
• W4387025105 hasConcept C71924100 @default.
• W4387025105 hasConcept C90924648 @default.
• W4387025105 hasConceptScore W4387025105C126322002 @default.
• W4387025105 hasConceptScore W4387025105C141071460 @default.
• W4387025105 hasConceptScore W4387025105C207103383 @default.
• W4387025105 hasConceptScore W4387025105C2776301958 @default.
• W4387025105 hasConceptScore W4387025105C2778661090 @default.
• W4387025105 hasConceptScore W4387025105C2778800853 @default.
• W4387025105 hasConceptScore W4387025105C2778810321 @default.
• W4387025105 hasConceptScore W4387025105C2779161974 @default.
• W4387025105 hasConceptScore W4387025105C2780868729 @default.
• W4387025105 hasConceptScore W4387025105C44249647 @default.
• W4387025105 hasConceptScore W4387025105C50382708 @default.
• W4387025105 hasConceptScore W4387025105C71924100 @default.

• next